EMA Authorised: Zepatier (elbasvir;grazoprevir) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA has authorised Zepatier (elbasvir/grazoprevir) for chronic hepatitis C infection with Merck Sharp & Dohme B.V. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Zepatier (elbasvir/grazoprevir)

Snippet

Status: Authorised. Therapeutic area: Hepatitis C, Chronic. MAH: Merck Sharp & Dohme B.V.. Decision date: 07/11/2025